The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: Friend or foe?

被引:65
作者
Andersen, J. B.
Hassel, B. A.
机构
[1] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[2] Dept Microbiol & Immunol, Baltimore, MD 21201 USA
关键词
interferon; cancer; ISG15; ubiquitin; ubiquitin-like protein;
D O I
10.1016/j.cytogfr.2006.10.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interferon-stimulated gene, 15 kDa (ISG15) is an interferon regulated gene that is induced as a primary response to diverse microbial and cell stress stimuli, and encodes the founding member of the ubiquitin-like protein family. ISG15 post-translationally modifies proteins via a pathway parallel to, and partially overlapping with, that of ubiquitin. In addition, ISG15 is released from cells to mediate extracellular cytokine-like activities. Although the biological activities of ISG15 have yet to be fully elucidated, it is clear that ISG15 has the capacity to modulate diverse cellular and physiologic functions. Consistent with this view, alterations in the ISG15 pathway have been identified in human tumors and in tumor cell lines. Here we review evidence of a role for ISG15 as an endogenous tumor suppressor that, when dysregulated in malignant cells, can be subverted to promote oncogenesis. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:411 / 421
页数:11
相关论文
共 120 条
[1]   Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer [J].
Andersen, J. B. ;
Aaboe, M. ;
Borden, E. C. ;
Goloubeva, O. G. ;
Hassel, B. A. ;
Orntoft, T. F. .
BRITISH JOURNAL OF CANCER, 2006, 94 (10) :1465-1471
[2]   Interferon-stimulated gene-15 (Isg15) expression is up-regulated in the mouse uterus in response to the implanting conceptus [J].
Austin, KJ ;
Bany, BM ;
Belden, EL ;
Rempel, LA ;
Cross, JC ;
Hansen, TR .
ENDOCRINOLOGY, 2003, 144 (07) :3107-3113
[3]  
Bani MR, 2004, MOL CANCER THER, V3, P111
[4]   Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses [J].
Beg, AA .
TRENDS IN IMMUNOLOGY, 2002, 23 (11) :509-512
[5]   Cancer immunotherapy: A treatment for the masses [J].
Blattman, JN ;
Greenberg, PD .
SCIENCE, 2004, 305 (5681) :200-205
[6]  
Boddy MN, 1996, ONCOGENE, V13, P971
[7]   Second-generation interferons for cancer: clinical targets [J].
Borden, EC ;
Lindner, D ;
Dreicer, R ;
Hussein, M ;
Peereboom, D .
SEMINARS IN CANCER BIOLOGY, 2000, 10 (02) :125-144
[8]   Oncogene-induced senescence as an initial barrier in lymphoma development [J].
Braig, M ;
Lee, S ;
Loddenkemper, C ;
Rudolph, C ;
Peters, AHFM ;
Schlegelberger, B ;
Stein, H ;
Dörken, B ;
Jenuwein, T ;
Schmitt, CA .
NATURE, 2005, 436 (7051) :660-665
[9]   Cancer - Suppressing cancer: The importance of being senescent [J].
Campisi, J .
SCIENCE, 2005, 309 (5736) :886-887
[10]   Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis [J].
Chen, ZB ;
Trotman, LC ;
Shaffer, D ;
Lin, HK ;
Dotan, ZA ;
Niki, M ;
Koutcher, JA ;
Scher, HI ;
Ludwig, T ;
Gerald, W ;
Cordon-Cardo, C ;
Pandolfi, PP .
NATURE, 2005, 436 (7051) :725-730